Accelerate Vaccine Development With Rapid Total Particle Quantification
Rapid viral quantification of manufacturing samples during the emergence of a novel pathogenic virus is critical to quickly developing a vaccine. Current techniques for determining the quantity of virus particles in a process sample, such as immunoassays, the plaque assay, TCID50, or measures of genomic content such as qPCR require a certain prior knowledge of the virus so that the correct cell lines can be utilized and the correct reagents manufactured. Building the suite of specific reagents for molecular or immunological studies can take weeks to months, with potentially devastating consequences during an emerging virus outbreak.
Here we demonstrate the capabilities of the Virus Counter® 3100 to allow detection of viral protein and nucleic acid, to directly quantify the total particle count of enveloped viral samples. This platform operates without the need for species- or strain-specific reagents. This technology can therefore improve time-to-result for critical experiments in vaccine manufacturing for a novel viruses.
Accelerate process development and speed to market of vaccines with real-time virus quantification
Use an innovative and universal technology for real-time titer insights that does not require prior knowledge of virus sequences
Use a precise and direct approach to quantify viruses rapidly and with confidence
Meet Our Expert
Antje Schickert, PhD
Product Manager Virus Analytics
Dr. Schickert earned her M.S. degree in Immunology and Cell Biology from the University of Tuebingen, Germany where she studied the immune evasion strategies of Human Papillomaviruses. She received her Ph.D. degree in Microbiology in a collaboration between the University of Michigan in Ann Arbor and the University of Tuebingen. She joined Sartorius in November 2016 as scientist responsible for product development and overtook responsibilities as product manager for Virus Analytics in 2019.